Correction to: "Dysregulated serum response factor triggers formation of hepatocellular carcinoma", [Hepatology, 61, (2015), 979-989], doi: 10.1002/hep.27539;Dysregulated serum response factor triggers formation of hepatocellular carcinoma

Hepatology

Volumn 61, Issue 3, 2015, Pages 979-989

  Ohrnberger, Stefan ^a   Thavamani, Abhishek ^a,b   Braeuning, Albert ^c   Lipka, Daniel B ^b   Kirilov, Milen ^b   Geffers, Robert ^d   Authenrieth, Stella E ^a   Römer, Michael ^a   Zell, Andreas ^a   Bonin, Michael ^c   Schwarz, Michael ^c   Schütz, Günther ^b   Schirmacher, Peter ^e   Plass, Christoph ^b   Longerich, Thomas ^e   Nordheim, Alfred ^a,b  

^a Kinderklinik Tuebingen   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ALPHA ACTININ 3; BETA CATENIN; CD11B ANTIGEN; CD63 ANTIGEN; EARLY GROWTH RESPONSE FACTOR 1; EARLY GROWTH RESPONSE FACTOR 2; LYMPHOID ENHANCER FACTOR 1; MATRIX METALLOPROTEINASE 14; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN C FOS; PROTEIN VP16; RAS PROTEIN; RHO FACTOR; SERUM RESPONSE FACTOR; SOMATOMEDIN B; UVOMORULIN; CTNNB1 PROTEIN, MOUSE; TRANSACTIVATOR PROTEIN;

AKR1C18 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AXIN2 GENE; BEX1 GENE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CODON; CONTROLLED STUDY; CPE GENE; CPG ISLAND; CTNNB1 GENE; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; FSTL3 GENE; FZD3 GENE; GENE EXPRESSION PROFILING; GENE LOCUS; GENE OVEREXPRESSION; GENOME IMPRINTING; H19 GENE; HEPATOBILIARY PARAMETERS; IGFALS GENE; IMMUNOREGULATION; KLRB1A GENE; KRT20 GENE; LIPID METABOLISM; LIVER CELL; LIVER CELL CARCINOMA; LIVER NODULE; LIVER WEIGHT TO BODY WEIGHT RATIO; LPL2 GENE; LY6D GENE; LYMPHOCYTIC INFILTRATION; MISSENSE MUTATION; MOUSE; NDRG2 GENE; NONHUMAN; ONCOGENE; PLAT1 GENE; PRIORITY JOURNAL; PSA1 GENE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SCD2 GENE; SDHA GENE; TCF7 GENE; TIMP1 GENE; TSPAN13 GENE; TSPAN8 GENE; UPREGULATION; VIL1 GENE; VIM GENE; WILD TYPE; ANIMAL; GENETICS; HUMAN; LIVER NEOPLASMS, EXPERIMENTAL; LYMPHOCYTE; MUTATION; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BETA CATENIN; CELL PROLIFERATION; CPG ISLANDS; DNA METHYLATION; GENE EXPRESSION PROFILING; HEPATOCYTES; HERPES SIMPLEX VIRUS PROTEIN VMW65; HUMANS; INSULIN-LIKE GROWTH FACTOR II; LIVER NEOPLASMS, EXPERIMENTAL; LYMPHOCYTES; MICE; MUTATION; SERUM RESPONSE FACTOR;

EID: 84923402301     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27799     Document Type: Erratum

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, Jeannot E, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007;45:42-52.
3. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012;44:694-698.
4. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009;69:7385-7392.
5. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006;130:1117-1128.
6. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010;29:4989-5005.
7. Xue W, Krasnitz A, Lucito R, Sordella R, Vanaelst L, Cordon-Cardo C, et al. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev 2008;22:1439-1444.
8. Lahoz A, Hall A. DLC1: a significant GAP in the cancer genome. Genes Dev 2008;22:1724-1730.
9. Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer 2002;2:133-142.
10. Durkin ME, Yuan BZ, Zhou X, Zimonjic DB, Lowy DR, Thorgeirsson SS, et al. DLC-1:a Rho GTPase-activating protein and tumour suppressor. J Cell Mol Med 2007;11:1185-1207.
11. Sahai E, Olson MF, Marshall CJ. Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility. EMBO J 2001;20:755-766.
12. Xia M, Land H. Tumor suppressor p53 restricts Ras stimulation of RhoA and cancer cell motility. Nat Struct Mol Biol 2007;14:215-223.
13. Olson EN, Nordheim A. Linking actin dynamics and gene transcription to drive cellular motile functions. Nat Rev Mol Cell Biol 2010;11:353-365.
14. Posern G, Treisman R. Actin' together: serum response factor, its cofactors and the link to signal transduction. Trends Cell Biol 2006;16:588-596.
15. Bai S, Nasser MW, Wang B, Hsu SH, Datta J, Kutay H, et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 2009;284:32015-32027.
16. Park MY, Kim KR, Park HS, Park BH, Choi HN, Jang KY, et al. Expression of the serum response factor in hepatocellular carcinoma: implications for epithelial-mesenchymal transition. Int J Oncol 2007;31:1309-1315.
17. Kato N, Yoshida H, Ono-Nita SK, Kato J, Goto T, Otsuka M, et al. Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. Hepatology 2000;32:405-412.
18. Muehlich S, Hampl V, Khalid S, Singer S, Frank N, Breuhahn K, et al. The transcriptional coactivators megakaryoblastic leukemia 1/2 mediate the effects of loss of the tumor suppressor deleted in liver cancer 1. Oncogene 2012;31:3913-3923.
19. Hampl V, Martin C, Aigner A, Hoebel S, Singer S, Frank N, et al. Depletion of the transcriptional coactivators megakaryoblastic leukaemia 1 and 2 abolishes hepatocellular carcinoma xenograft growth by inducing oncogene-induced senescence. EMBO Mol Med 2013;5:1367-1382.
20. Sandstrom J, Heiduschka P, Beck SC, Philippar U, Seeliger MW, Schraermeyer U, et al. Degeneration of the mouse retina upon dysregulated activity of serum response factor. Mol Vis 2011;17:1110-1127.
21. Schratt G, Weinhold B, Lundberg AS, Schuck S, Berger J, Schwarz H, et al. Serum response factor is required for immediate-early gene activation yet is dispensable for proliferation of embryonic stem cells. Mol Cell Biol 2001;21:2933-2943.
22. Neumann O, Kesselmeier M, Geffers R, Pellegrino R, Radlwimmer B, Hoffmann K, et al. Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors. Hepatology 2012;56:1817-1827.
23. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004;91:355-358.
24. Wiebel FF, Rennekampff V, Vintersten K, Nordheim A. Generation of mice carrying conditional knockout alleles for the transcription factor SRF. Genesis 2002;32:124-126.
25. Stecca BA, Nardo B, Chieco P, Mazziotti A, Bolondi L, Cavallari A. Aberrant dipeptidyl peptidase IV (DPP IV/CD26) expression in human hepatocellular carcinoma. J Hepatol 1997;27:337-345.
26. Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 2011;479:547-551.
27. Esnault C, Stewart A, Gualdrini F, East P, Horswell S, Matthews N, et al. Rho-actin signaling to the MRTF coactivators dominates the immediate transcriptional response to serum in fibroblasts. Genes Dev 2014;28:943-958.
28. Marquardt JU, Seo D, Andersen JB, Gillen MC, Kim MS, Conner EA, et al. Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits. J Hepatol 2014;60:346-353.
29. Silviera ML, Smith BP, Powell J, Sapienza C. Epigenetic differences in normal colon mucosa of cancer patients suggest altered dietary metabolic pathways. Cancer Prev Res (Phila) 2012;5:374-384.
30. Hollenhorst PC, Ferris MW, Hull MA, Chae H, Kim S, Graves BJ. Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. Genes Dev 2011;25:2147-2157.
31. Pritchard MT, Malinak RN, Nagy LE. Early growth response (EGR)-1 is required for timely cell-cycle entry and progression in hepatocytes after acute carbon tetrachloride exposure in mice. Am J Physiol Gastrointest Liver Physiol 2011;300:G1124-1131.
32. Schirmacher P, Held WA, Yang D, Chisari FV, Rustum Y, Rogler CE. Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth. Cancer Res 1992;52:2549-2556.
33. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006;12:410-416.
34. Guo X, Keyes WM, Papazoglu C, Zuber J, Li W, Lowe SW, et al. TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol 2009;11:1451-1457.